Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Vistin Pharma ASA's share price for the quarter that ended in Mar. 2026 was €1.895. Vistin Pharma ASA's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 44.35 Mil. Therefore, Vistin Pharma ASA's market cap for the quarter that ended in Mar. 2026 was €84.03 Mil.
Vistin Pharma ASA's quarterly market cap
declined
from Sep. 2025 (€84.92 Mil) to Dec. 2025 (€76.27 Mil) but then
increased
from Dec. 2025 (€76.27 Mil) to Mar. 2026 (€84.03 Mil).
Vistin Pharma ASA's annual market cap
declined
from Dec. 2023 (€89.58 Mil) to Dec. 2024 (€88.25 Mil) and
declined
from Dec. 2024 (€88.25 Mil) to Dec. 2025 (€76.27 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Vistin Pharma ASA's Enterprise Value for Today is €77.90 Mil.
Vistin Pharma ASA (STU:VP4) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Vistin Pharma ASA Market Cap Related Terms
Vistin Pharma ASA Market Cap Historical Data
* Premium members only.
The historical data trend for Vistin Pharma ASA's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistin Pharma ASA Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's Market Cap distribution charts can be found below:
* The bar in red indicates where Vistin Pharma ASA's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Vistin Pharma ASA's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vistin Pharma ASA (STU:VP4) has a Market Cap of €79.28 Mil as of Jul. 06, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Vistin Pharma ASA and its competitors. According to the industry distribution chart, Vistin Pharma ASA ranks #628 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 61.3%.
Is Vistin Pharma ASA's Market Cap too high?
Vistin Pharma ASA's current Market Cap is €79.28 Mil. Based on the distribution chart, Vistin Pharma ASA ranks #628 out of 1024 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Vistin Pharma ASA has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vistin Pharma ASA ranks #628 out of 1024 companies for Market Cap. This places Vistin Pharma ASA in the lower half of its industry. The industry median Market Cap is 214.89. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 214.89, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Vistin Pharma ASA and its competitors. For the Drug Manufacturers industry, the median Market Cap is 214.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistin Pharma ASA's current Market Cap is €79.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (STU:VP4) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.26, compared to a current price of €1.80 — trading 20.6% below its estimated fair value. The current Market Cap is €79.28 Mil. Vistin Pharma ASA's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Vistin Pharma ASA (STU:VP4), the current Market Cap is €79.28 Mil as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistin Pharma ASA (STU:VP4) Overvalued in 2026?
Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued.
The current stock price of €1.80 is trading 20.6% below its estimated GF Value™ of €2.26.
GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.
Key valuation signals for STU:VP4:
Market Cap: €79.28 Mil
GF Value™: €2.26 vs. price of €1.80 (20.6% below fair value)
No single metric tells the full story. See the STU:VP4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
77GF Score
Get the complete analysis for STU:VP4
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:VP4 has been successfully added to your 
